Pharvaris NV
NASDAQ:PHVS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Gulshan Polyols Ltd
NSE:GULPOLY
|
IN |
|
Sheela Foam Ltd
NSE:SFL
|
IN |
|
Argentina Lithium & Energy Corp
XTSX:LIT
|
CA |
|
M
|
MS Group Holdings Ltd
HKEX:1451
|
HK |
|
G
|
Galp Energia SGPS SA
ELI:GALP
|
PT |
|
R
|
Roadside Real Estate PLC
LSE:ROAD
|
UK |
|
VST Tillers Tractors Ltd
NSE:VSTTILLERS
|
IN |
|
H
|
HLE Glascoat Ltd
NSE:HLEGLAS
|
IN |
|
N
|
Namhwa Industrial Co Ltd
KOSDAQ:111710
|
KR |
Pharvaris NV
Research & Development
Pharvaris NV
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharvaris NV
NASDAQ:PHVS
|
Research & Development
-€124.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Pharvaris NV
Glance View
Pharvaris NV is a clinical-stage biopharmaceutical company. The company is headquartered in Leiden, Zuid-Holland and currently employs 34 full-time employees. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
See Also
What is Pharvaris NV's Research & Development?
Research & Development
-124.5m
EUR
Based on the financial report for Dec 31, 2025, Pharvaris NV's Research & Development amounts to -124.5m EUR.
What is Pharvaris NV's Research & Development growth rate?
Research & Development CAGR 5Y
-45%
Over the last year, the Research & Development growth was -26%. The average annual Research & Development growth rates for Pharvaris NV have been -29% over the past three years , -45% over the past five years .
